Shares
Here you will find information on Sartorius Stedim Biotech shares (DIM).
Click here for Sartorius preference shares (SRT3) and Sartorius ordinary shares (SRT)
Stock Chart
Stock Chart
Shares Overview
Shares Overview
ISIN | FR0013154002 |
Stock exchange | Euronext Paris |
Market segment | Local Securities - Compartment A (Large Caps) |
Indixes | SBF 120 | CAC Next 20 | CAC Large 60 | CAC All-Tradable | CAC All Shares | CAC Healthcare | MSCI France | STOXX Europe 600 |
Capital stock | 19,466,081 euros |
Number of shares | 97,330,405 |
- thereof Sartorius AG | 71.5% |
- thereof free float | 28.5% |
Voting rights | ~166.0 million |
- thereof Sartorius AG | ~83.0% |
- thereof free float | ~17.0% |
Sartorius Stedim Biotech is currently covered by 16 sell-side analysts. The following list shows their latest recommendations for Sartorius Stedim Biotech shares.
Institution | Analyst | Date | Target Price | Recommendation |
Berenberg | Odysseas Manesiotis | 24.04.2024 | 243.00 | Buy |
Barclays | Charles Pitman | 23.04.2024 | 200.00 | Equalweight |
UBS | Matthew Weston | 22.04.2024 | 232.00 | Neutral |
JP Morgan | Richard Vosser | 22.04.2024 | 290.00 | Overweight |
HSBC | Sezgi Özener | 19.04.2024 | 360.00 | Buy |
Exane | Hugo Solvet | 19.04.2024 | 245.00 | Outperform |
Kepler Chevreux | Oliver Reinberg | 19.04.2024 | 315.00 | Buy |
Intron Health | Naresh Chouhan | 19.04.2024 | 165.00 | Sell |
Morgan Stanley | Thibault Boutherin | 19.04.2024 | 250.00 | Hold |
CIC Market Solutions | Arnaud Cadart | 19.04.2024 | 210.00 | Hold |
Morningstar | Jay Lee | 19.04.2024 | 240.00 | -- |
Jefferies | James Vane-Tempest | 18.04.2024 | 330.00 | Buy |
Bernstein | Nithya Balasubramanian | 21.03.2024 | 271.00 | Outperform |
Alpha Value | Virendra Chauhan | 30.01.2024 | 283.00 | Buy |
Oddo BHF | Oliver Metzger | 26.01.2024 | 205.00 | Hold |
Gilbert Dupont | Guillaume Cuvillier | 19.06.2023 | 280.00 | Buy |
Disclaimer
The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.
Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.
Sartorius Stedim Biotech S.A.’s issued capital amounted to €19.5 million as of February 07, 2024, and was divided into 97,330,405 shares, each with a calculated par value of €0.20. As some of the shares convey double voting rights, there were a total of 165,581,058 voting rights as of the reporting date.
As of February 7, 2024, Sartorius AG holds 71.5% of the share capital and 83.0% of the outstanding voting rights. The remaining 28.5% of the shares are in free float; corresponding to 17.0% of the outstanding voting rights.